Case Report
W. is a 65-year old non-smoking Caucasian female who had sicca symptoms without sclerodactylia for twenty eight years. On laboratory testing, she had positive ANA, rheumatoid factor, elevated erythrocyte sedimentation rate, elevated Anti Ro/SSA, normal serum creatinine and normal liver function tests and multiple pulmonary nodules on chest X ray since 1995. Patient developed progressive dyspnea and became oxygen dependent since 2005. A CT scan of the chest done prior to mycophenolate mofetil (MMF) therapy showed extensive bullous emphysematous disease and multiple calcified nodules in both lung fields. There was no evidence for pulmonary embolism, axillary or mediastinal adenopathey.
Patient had an abdominal fat pad biopsy and (Table 1) but not in her pulmonary diffusion capacity or her chest X ray ( Figure 1 ). The residual nodular opacities probably represented calcifications.
Discussion
Although Sjogren's syndrome (SS) has been reported to have been associated with localized amyloidosis ,1-4 only isolated case reports of SS have been described in association with systemic primary amyloidosis. 5 One case of multiple myeloma and primary amyloidosis mimick- ing SS has been reported. 6 There are few reported cases of systemic light chain fragments that do not have the biochemical characteristics to form amyloid fibrils. 6, 7 Therefore the light chain deposition disease is labeled as a non-amyloid monoclonal immuno globulin light chain.
We believe that MMF was efficacious in the treatment of our patient who had SS with pulmonary manifestations. MMF is a selective inhibitor of Inosine monophosphate (IMP) dehydrogenase which is an important enzyme in de novo purine synthesis that converts Inosine monophosphate to xanthine monophosphate. Inhibition of IMP dehydrogenase, expressed by results in decreased nucleotide synthesis by the de novo pathway. The antiproliferative effect of MMF mainly affects activated T-and B-lymphocytes because their proliferation is critically dependent on the novo purine syntesis. MMF preferentially binds to type II isoform of IMP dehydrogenase, expressed by activated lymphocytes. 8 MMF however could lead to immunosuppression through other mechanisms, including apoptosis of activated T-lymphocytes, and inhibition of adhesion molecule expression and lymphocyte recruitment. 9 Since both T and B cells have been suggested to have a pivotal role in the immunopathogensis of primary SS, 10, 11 MMF may be a promising drug in the management of SS and the lymphoproliferative disorders associated with this syndrome.
Our case demonstrated improvement of pulmonary function tests as well as her pulmonary complaints upon therapy with MMF. However our patient diffusion capacity to carbon monoxide (DLCO) did not change following MMF therapy. We do realize that further studies and randomized clinical trials in similar patients are warranted to establish the efficacy of MMF in the management of SS with light chain depositon disease. Recent reports have indicated however no improvement in survival of patients with amyloidsis associated with inflammatory rheumatic diseases.
